BTX-A51

N/A

Report date: 2024/04/11 10:47:57
NME

Base Information

Drug NameBTX-A51
Drug Alias NameBTX-A51PHM®-A51 PROTACs
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitorsCyclin-dependent kinase 7 inhibitorsCasein kinase I isoform alpha inhibitors
TargetsCyclin-dependent kinase 9Cyclin-dependent kinase 7Casein kinase I isoform alpha
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursMyelodysplastic Syndromes +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesYissum
China Registration ClassN/A

Develop Information

Active CompaniesEdgewood Oncology Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursMyelodysplastic Syndromes +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A